Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at William Blair issued their Q4 2018 earnings per share (EPS) estimates for Sarepta Therapeutics in a research note issued on Friday. William Blair analyst T. Lugo forecasts that the biotechnology company will earn ($0.39) per share for the quarter. William Blair currently has a “Outperform” rating on the stock.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. During the same period last year, the firm posted ($1.19) earnings per share. The company’s quarterly revenue was up 350000.0% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/william-blair-weighs-in-on-sarepta-therapeutics-inc-s-q4-2018-earnings-srpt/1608429.html.

A number of other analysts have also recently weighed in on SRPT. Credit Suisse Group reissued an “outperform” rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a research note on Monday. Morgan Stanley restated an “equal weight” rating and set a $31.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 30th. Leerink Swann restated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday, July 3rd. Robert W. Baird reaffirmed an “outperform” rating and set a $96.00 price objective (down from $102.00) on shares of Sarepta Therapeutics in a report on Friday, July 21st. Finally, Zacks Investment Research raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $62.79.

Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up 1.44% during midday trading on Monday, hitting $49.89. 1,086,084 shares of the company were exchanged. The stock’s market cap is $3.21 billion. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $63.03. The stock’s 50-day moving average is $42.47 and its 200-day moving average is $35.98.

In other news, SVP Shamim Ruff sold 12,138 shares of the business’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $42.97, for a total transaction of $521,569.86. Following the completion of the sale, the senior vice president now owns 27,312 shares in the company, valued at $1,173,596.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Douglas S. Ingram purchased 47,058 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were purchased at an average cost of $42.50 per share, for a total transaction of $1,999,965.00. Following the purchase, the chief executive officer now directly owns 382,058 shares of the company’s stock, valued at $16,237,465. The disclosure for this purchase can be found here. Insiders sold a total of 78,056 shares of company stock worth $3,224,208 over the last quarter. Corporate insiders own 9.60% of the company’s stock.

A number of institutional investors have recently bought and sold shares of SRPT. BlackRock Inc. boosted its holdings in Sarepta Therapeutics by 4,403.1% in the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock valued at $156,664,000 after acquiring an additional 5,175,193 shares during the last quarter. Camber Capital Management LLC acquired a new stake in Sarepta Therapeutics in the first quarter worth about $39,960,000. State Street Corp raised its holdings in Sarepta Therapeutics by 21.2% during the 1st quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after purchasing an additional 559,342 shares during the last quarter. Voya Investment Management LLC raised its holdings in Sarepta Therapeutics by 2,786.1% during the 2nd quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after purchasing an additional 548,826 shares during the last quarter. Finally, HealthCor Management L.P. raised its holdings in Sarepta Therapeutics by 31.1% during the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after purchasing an additional 481,890 shares during the last quarter. Institutional investors and hedge funds own 65.41% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.